Form 4: Enanta Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Mark G. Foletta, a director at Enanta Pharmaceuticals, acquired stock options exercisable for 15,700 shares of common stock on March 6, 2024.
Summary
- On March 6, 2024, Mark G. Foletta, a director of Enanta Pharmaceuticals, acquired stock options to purchase 15,700 shares of the company's common stock.
- The exercise price of these options is $15.66 per share.
- The options vest monthly over one year, starting March 6, 2024, with the final installment vesting before the 2025 annual meeting of stockholders.
- The options expire on March 6, 2034.
- Following the transaction, Foletta directly owns options for 15,700 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction provides insight to stakeholders regarding director compensation and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of the stock option grant. |
| 03/06/2024 | Vesting start date for the stock options. |
| 03/06/2034 | Expiration date of the stock options. |
| 03/08/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.